Sign In
Buy ALGS
$4.23
-0.0900 (-2.08%)
At Close: Jul 31, 2026
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
10:30am, Monday, 10'th Mar 2025
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago.
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
08:00am, Monday, 10'th Mar 2025
SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes thr
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
08:00am, Monday, 03'rd Mar 2025
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-c
Aligos Therapeutics Announces $105 Million Private Placement Financing
07:00am, Wednesday, 12'th Feb 2025
Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSW
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 13'th Dec 2024
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving pa
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
01:30pm, Tuesday, 19'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeuti
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates
07:06pm, Wednesday, 06'th Nov 2024
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to loss of $10.25 per share a year ago.
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
04:05pm, Wednesday, 06'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
08:30am, Thursday, 31'st Oct 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting .
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 11'th Oct 2024
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving pa
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
08:00am, Tuesday, 01'st Oct 2024
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in
Aligos Therapeutics to Present at Investor Conferences in October
08:00am, Monday, 30'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
08:00am, Thursday, 19'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
05:00pm, Wednesday, 18'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving p
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 13'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving p
